Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Suffers Reversal On “Reverse Payments” Enforcement

This article was originally published in The Pink Sheet Daily

Executive Summary

The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.

You may also be interested in...



Unsettling Settlements: FTC Alarmed By Increasing Brand/Generic Deals

The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.

AstraZeneca Collaborations Moving From “Deals” To “Relationships”

Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.

Pharmacogenetic Dosing Recommendations Sorely Needed By Clinicians, Formularies, SACGHS Says

Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel